Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rocket Pharmaceuticals, Inc. - Common Stock
(NQ:
RCKT
)
2.305
+0.065 (+2.90%)
Delayed Quote
Updated: 9:57 AM EDT, Oct 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rocket Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
↗
May 27, 2025
Via
Benzinga
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
↗
May 27, 2025
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."
Via
Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session.
↗
May 27, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 27, 2025
Via
Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month
↗
January 06, 2025
Via
Benzinga
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
May 27, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
↗
May 16, 2025
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease.
Via
Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
↗
May 16, 2025
Via
Benzinga
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
May 15, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
May 09, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
May 08, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
↗
April 21, 2025
Via
Benzinga
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility
↗
April 17, 2025
Despite market volatility, these stocks are seeing strong buys by insiders.
Via
Talk Markets
Topics
Stocks / Equities
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
↗
April 15, 2025
Via
Benzinga
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 03, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
February 27, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Rocket Pharmaceuticals, Inc
Via
Business Wire
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
December 11, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 10, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
3 Small-Cap Stocks That Are Ready to Rocket Higher
November 27, 2024
With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity
Via
MarketBeat
Topics
Government
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
November 26, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
↗
November 19, 2024
Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health.
Via
Benzinga
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
November 18, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
November 12, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
November 08, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
November 07, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
September 17, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
September 10, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
↗
August 26, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
